Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating some of our most difficult conditions ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

New research highlights how GLP-1 receptor agonists influence gut bacteria, offering insights into their broader metabolic and anti-inflammatory benefits. Study: Effects of GLP-1 Analogues and ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...

Just days after Pfizer pulled its experimental obesity pill, Eli Lilly announced promising results for its oral GLP-1. The pharma giant announced Thursday morning that its oral GLP-1 drug advanced ...